Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent ...

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increasing use of U.S. regulatory-approved agents -- Pfizer's Lyrica , Eli Lilly/Boehringer Ingelheim's Cymbalta/Xeristar and Forest Laboratories' Savella -- will drive 4.2 percent annual growth in the fibromyalgia drug market from 2009 to 2018.